Profile data is unavailable for this security.
About the company
Pharma Foods International Co., Ltd. is a Japan-based company mainly engaged in mail order business and functional materials business. The Company operates through three business segments. The Mail Order segment is engaged in the sale of supplement Tamagosamin, cosmetics Pearl Skin Lanchel and Derma QII Mild Peeling Gel, through advertising media such as televisions and radios. The Functional Materials segment is engaged in the development and sale of functional materials such as GABA, Bonepep, Folic Acid eggs and Chicken Egg Antibody. The Company is also engaged in the planning and sale of original equipment manufacturer (OEM) products such as supplements and beverages. The Biomedical segment is engaged in the antibody contract manufacture business for drug discovery and diagnostics, and life science information (LSI) business for analysis and efficacy evaluation test of materials and products.
- Revenue in JPY (TTM)62.15bn
- Net income in JPY3.21bn
- Incorporated1997
- Employees642.00
- LocationPharma Foods International Co Ltd1-49, Goryo-Ohara, Nishikyo-kuKYOTO-SHI 615-8245JapanJPN
- Phone+81 753948600
- Fax+81 753940099
- Websitehttps://www.pharmafoods.co.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pell Bio Med Technology Co Ltd | 85.14m | -1.91bn | 24.41bn | -- | -- | 3.76 | -- | 286.69 | -8.02 | -8.02 | 0.341 | 23.77 | 0.0132 | 10.43 | 4.23 | -- | -29.90 | -- | -34.86 | -- | -113.22 | -- | -2,262.16 | -- | 7.19 | -- | 0.0985 | -- | 5.11 | -- | -73.27 | -- | -- | -- |
| TOT Biopharm International Co Ltd | 20.79bn | 191.52m | 25.64bn | 572.00 | 125.66 | 1.66 | 18.90 | 1.23 | 0.0135 | 0.0135 | 1.46 | 1.02 | 0.6899 | 2.44 | 6.40 | 1,921,852.00 | 0.6356 | -20.01 | 0.8392 | -25.21 | 72.02 | 74.74 | 0.9212 | -68.53 | 1.63 | 2.98 | 0.3465 | -- | 76.54 | 81.88 | 24.36 | -- | 21.04 | -- |
| Race Oncology Ltd | 83.66m | -1.39bn | 26.98bn | -- | -- | 14.65 | -- | 322.49 | -0.0839 | -0.0839 | 0.0051 | 0.1075 | 0.0355 | -- | 0.9201 | -- | -58.97 | -46.49 | -63.04 | -48.68 | -- | -- | -1,659.82 | -2,995.74 | -- | -- | 0.00 | -- | 40.68 | 116.86 | -39.26 | -- | -- | -- |
| Jacobio Pharmaceuticals Group Co Ltd | 495.31m | -7.73bn | 27.41bn | 298.00 | -- | 1.42 | -- | 55.34 | -0.5073 | -0.5073 | 0.0325 | 1.25 | 0.016 | -- | 2.41 | 83,815.43 | -24.89 | -45.76 | -28.66 | -49.30 | 3.45 | -- | -1,560.88 | -372.22 | -- | -- | 0.1794 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
| Vimta Labs Ltd | 5.72bn | 743.14m | 27.88bn | 1.43k | 37.89 | -- | 20.56 | 4.87 | 18.32 | 18.32 | 141.14 | -- | -- | -- | -- | 2,216,604.00 | -- | 10.53 | -- | 12.77 | 76.48 | 73.65 | 12.98 | 12.16 | -- | 26.56 | -- | 5.58 | 0.0223 | 8.40 | -14.87 | 10.13 | 35.88 | 0.00 |
| Heartseed Inc | -100.00bn | -100.00bn | 27.96bn | 39.00 | -- | 4.53 | -- | -- | -- | -- | -- | 277.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 20.01 | -- | 0.0011 | -- | -30.93 | -- | -4.30 | -- | -- | -- |
| Mabpharm Ltd | 3.24bn | -4.42bn | 28.34bn | 297.00 | -- | 11.52 | -- | 8.75 | -0.0546 | -0.0546 | 0.04 | 0.0304 | 0.164 | 0.1937 | 3.26 | 475,468.60 | -22.38 | -21.42 | -31.11 | -27.49 | 86.91 | -- | -136.47 | -486.40 | 0.6836 | -22.44 | 0.679 | -- | 55.87 | -- | 0.694 | -- | -26.85 | -- |
| Pharma Foods International Co., Ltd. | 62.15bn | 3.21bn | 29.63bn | 642.00 | 8.98 | 2.47 | 7.20 | 0.4768 | 113.47 | 113.47 | 2,185.12 | 412.69 | 1.71 | 2.10 | 14.00 | 96,802,180.00 | 8.81 | 8.63 | 25.38 | 22.06 | 78.45 | 80.64 | 5.16 | 4.13 | 0.8875 | 81.16 | 0.5933 | 27.65 | -9.37 | 42.62 | 4.02 | 45.01 | 28.23 | -- |
| Imugene Ltd | 0.00 | -15.04bn | 34.38bn | 0.00 | -- | 2.85 | -- | -- | -0.0211 | -0.0211 | 0.00 | 0.0162 | 0.00 | -- | -- | -- | -85.91 | -44.42 | -95.62 | -47.46 | -- | -- | -- | -- | -- | -- | 0.0053 | -- | -- | -- | -294.78 | -- | 136.28 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 03 Oct 2024 | 836.50k | 2.88% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 816.57k | 2.81% |
| Nikko Asset Management Co., Ltd.as of 04 Oct 2024 | 382.40k | 1.32% |
| Daiwa Asset Management Co. Ltd.as of 30 Sep 2024 | 369.90k | 1.27% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 307.50k | 1.06% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 166.10k | 0.57% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 03 Oct 2024 | 162.30k | 0.56% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 82.50k | 0.28% |
| BlackRock Fund Advisorsas of 02 Oct 2024 | 81.50k | 0.28% |
| Invesco Asset Management (Japan) Ltd.as of 27 Apr 2023 | 75.30k | 0.26% |
